CHTP +3.66% today announced the presentation of an integrated analysis of data from two pivotal multicenter, placebo-controlled, randomized clinical trials showing that NORTHERA™ (droxidopa) had demonstrated an acceptable safety profile and demonstrated a statistically significant difference in efficacy compared to placebo for improving the symptoms of neurogenic orthostatic hypotension (NOH) in a population comprised chiefly of patients with Parkinson's Disease (PD).
mariyatrader: Yes, it is essentially old news . The two trials covered in this poster (studies 301 and 306B) were the basis for the FDA approval. The poster groups the data from the studies and provides a bit more color than previously seen. Note that no mention was made of the longer-term studies 302 and 303 that did not reach statistical significance.
delayabout: The poster presentation has no effect on the deal with Lundbeck, and should be nothing new to any company that would have an interest in acquiring CHTP. While the poster certainly doesn't guarantee future CVR payments, it does help as it draws more attention from those physicians wo will be prescribing it.
PLUG: See my Seeking Alpha article (find it in the News section of the summary) for more on the CVR payments.
Thanks very much for that but the Lundbeck deal is still a done deal no ?.....This news still doesn't guarantee the extra 25% over the next 3 years.....would it attract more buyers in at this late stage ?